维利帕尼联合局部照射与替莫唑胺治疗新诊断高级别胶质瘤的2期试验:儿童肿瘤协作组研究
这项单臂非随机2期试验评估维利帕尼联合放疗序贯维利帕尼与替莫唑胺能否改善新诊断HGG患儿的无进展生存,对照为临床及分子特征匹配的历史队列。两个分层均因无效提前关闭,1年EFS在IDH野生型组为23%、IDH突变型组为57%,方案耐受良好但未改善结局。
要点
- 维利帕尼+放疗序贯替莫唑胺未改善新诊断儿童HGG的结局。
- IDH野生型组1年无事件生存率23%,1年总生存率64%。
- IDH突变型组1年无事件生存率57%,1年总生存率93%。
核心结论
- 维利帕尼联合放疗序贯替莫唑胺耐受良好,但相比接受更高剂量烷化剂化疗的临床与分子匹配历史对照,未能改善结局。
- 两个分层均在计划中期分析后因无效关闭入组。
- 快速中心病理复核与分子检测用于筛选合格患者是可行的。
研究设计与样本
- 单臂、非随机2期临床试验,纳入新诊断、非转移性、无H3 K27M或BRAF突变的高级别胶质瘤儿童患者。
- 术后经快速中心病理复核和分子检测筛选,合格患者入组分层1(IDH野生型)或分层2(IDH突变型)。
- 对照为临床和分子特征高度匹配的历史队列患者个体数据。
- 分层1有23例合格患者入组并接受方案治疗,分层2有14例合格患者入组并接受方案治疗。
主要发现
- 分层1的1年无事件生存率为23%(标准误SE=9%),1年总生存率为64%(SE=10%)。
- 分层2的1年无事件生存率为57%(SE=13%),1年总生存率为93%(SE=0.7%)。
- 两个分层均在计划中期分析后因无效关闭入组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcome for pediatric patients with high-grade glioma (HGG) remains poor. Veliparib, a potent oral poly(adenosine diphosphate-ribose) polymerase (PARP) 1/2 inhibitor, enhances the activity of radiotherapy and DNA-damaging chemotherapy. METHODS: We conducted a single-arm, non-randomized phase 2 clinical trial to determine whether treatment with veliparib and radiotherapy, followed by veliparib and temozolomide, improves progression-free survival in pediatric patients with newly diagnosed HGG without H3 K27M or BRAF mutations, compared to patient-level data from historical cohorts with closely matching clinical and molecular features. Following surgical resection, newly diagnosed children with non-metastatic HGG were screened by rapid central pathology review and molecular testing. Eligible patients were enrolled on Stratum 1 (IDH wild-type) or Stratum 2 (IDH mutant). RESULTS: Both strata were closed to accrual for futility after planned interim analyses. Among the 23 eligible patients who enrolled on Stratum 1 and received protocol therapy, the 1-year event-free survival (EFS) was 23% (standard error, SE = 9%) and the 1-year overall survival (OS) was 64% (SE = 10%). Among the 14 eligible patients who enrolled on Stratum 2 and received protocol therapy, the 1-year EFS was 57% (SE = 13%) and 1-year OS was 93% (SE = 0.7%). CONCLUSIONS: Rapid central pathology review and molecular testing for eligibility were feasible. The protocol therapy including radiation, veliparib, and temozolomide was well tolerated but failed to improve outcomes compared to clinically and molecularly matched historical control cohorts treated with higher doses of alkylator chemotherapy. CLINICALTRIALS.GOV IDENTIFIER: NCT03581292 (first posted: July 10, 2018).
引用
- Karajannis MA, Onar-Thomas A, Lin T, et al. Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study. Neuro Oncol. 2025. PMID: 39560182. doi:10.1093/neuonc/noae247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。